2019 | An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14). | Chen, Ming-Huang; Chou, Wen-Chi; Hsiao, Chin-Fu; Liu, Yi-Chang; Hsu, Chiun; Yanshen, Shan; Hung, Yi-Ping; Hsieh, Chia-Hsun; Chiu, Chao-Hua; Liu, Ta-Chih; Cho, Shih-Feng; Liu, Tsang-Wu; Chao, Yee; YI-PING HUNG | Journal of Clinical Oncology | 0 | 0 | |
2022 | Optimizing margin status for improving prognosis in patients with oral cavity squamous cell carcinoma: A retrospective study from the two highest-volume Taiwanese hospitals | Liao, Chun-Ta; Lee, Li-Yu; Lee, Shu-Ru; Ng, Shu-Hang; Liu, Tsang-Wu; Chien, Chih-Yen; Lin, Jin-Ching; CHENG-PING WANG ; Terng, Shyuang-Der; Hua, Chun-Hung; Chen, Tsung-Ming; Chen, Wen-Cheng; Tsai, Yao-Te; Kang, Chung-Jan; Tsai, Chi-Ying; Chu, Ying-Hsia; Lin, Chien-Yu; Fan, Kang-Hsing; Wang, Hung-Ming; Hsieh, Chia-Hsun; Yeh, Chih-Hua; Lin, Chih-Hung; Tsao, Chung-Kan; Yen, Tzu-Chen; Cheng, Nai-Ming; Fang, Tuan-Jen; Huang, Shiang-Fu; Lee, Li-Ang; Fang, Ku-Hao; Wang, Yu-Chien; Lin, Wan-Ni; Hsin, Li-Jen; Wen, Yu-Wen | Frontiers in oncology | 0 | 0 | |